Interdependence of coagulation with immunotherapy and BRAF/MEK inhibitor therapy: results from a prospective study.

ABSTRACT: Immune checkpoint inhibitor (ICI) therapies effectively treat a broadening spectrum of cancer entities but induce various immune-related side effects (irAEs). Recent reports suggest a correlation between ICI-induced systemic inflammation and thromboembolic events as well as an increased effectiveness by coadministration of anticoagulants. With cancer patients having a higher risk of thrombotic events per se, it is crucial to dissect and characterize the mechanisms that cause pro-coagulative effects induced by systemic tumor therapies and their potential interplay with anti-tumor response. A total of 31 patients with advanced skin cancer treated with either ICIs (n = 24) or BRAF/MEK inhibitors (n = 7) were longitudinally assessed for blood and coagulation parameters before as well as 7, 20

SUBMITTER: Beckmann M 

PROVIDER: S-EPMC11531462 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature